Zobrazeno 1 - 10
of 1 076
pro vyhledávání: '"PD‐1 inhibitors"'
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2505-2514 (2024)
Xin Hong,1,* Di Hu,2,* Wen-Jie Zhou,3,* Xiu-De Wang,4 Li-Hua Huang,5 Tian-An Huang,1 Yi-Wei Guan,1 Jingyu Qian,6 Wen-Bin Ding1 1Department of Interventional Radiology, Affiliated Hospital 2 of Nantong University, Nantong, People’s Repub
Externí odkaz:
https://doaj.org/article/1494f9cf251643d4bdc3575e943993f1
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 5, Pp 1611-1614 (2024)
Abstract Immune checkpoint inhibitors such as the programmed cell death‐1 (PD‐1) inhibitors, pembrolizumab and nivolumab, are frontline treatments for several types of solid‐organ malignancies. However, cutaneous adverse effects with PD‐1 inh
Externí odkaz:
https://doaj.org/article/3cde5fcb94764132b3681a89de1d4f66
Publikováno v:
Biologics: Targets & Therapy, Vol Volume 18, Pp 313-326 (2024)
Hai-Li Wang,1 Shi-Xia Zhou,1 Jing Kuang,1 Sa Xiao,1 Min Li2 1Department of Oncology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450014, People’s Republic of China; 2Department of Oncology, Zhengzhou People’s Hospital, Zhen
Externí odkaz:
https://doaj.org/article/555d40dc1cc54df4818ab6092069858f
Autor:
Wenjuan Tian, Yulan Ren, Jing Lu, Chuyu Jing, Wei Zhang, Haiming Li, Tingting Wang, Zhiguo Hou, Ting Yang, Wenqing Zhu, Yi Zhang, Boer Shan, Huijuan Yang, Xi Cheng, Huaying Wang
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background The combination of anti-programmed death 1 (PD-1) inhibitors and tyrosine kinase inhibitors is an effective treatment strategy in endometrial cancer. We aimed to explore the efficacy and safety of camrelizumab plus apatinib as an
Externí odkaz:
https://doaj.org/article/add83a36851b4bfe963c2d118c5077c9
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundNumerous third-line treatment options exist for colorectal cancer. This study aims to assess the efficacy and safety of third-line therapies, including TKIs (fruquintinib, regorafenib) combined with PD-1 inhibitors, and trifluridine/tipirac
Externí odkaz:
https://doaj.org/article/d4ceb7601e164bff9b5171e3cb160635
Autor:
Yunyi Du, Ying Zhang, Wenqi Zhao, Yuexiang Zhang, Fei Su, Xiaoling Zhang, Weiling Li, Wenqing Hu, Yongai Li, Jun Zhao
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Immune-related adverse events (irAEs) impact outcomes, with most research focusing on early prediction (baseline data), rather than near-term prediction (one cycle before the occurrence of irAEs and the current cycle). We aimed to explore the near-te
Externí odkaz:
https://doaj.org/article/6ddbeb11c972409dae8f6bd9bc4970d2
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Immunotherapy, led by programmed cell death protein-1 (PD-1) inhibitors, has emerged as a prominent antitumor therapy, yet prognostic challenges persist in pancreatic cancer (PC). This retrospective, single-center study evaluated prognostic factors i
Externí odkaz:
https://doaj.org/article/75e86e0bcf7242eb9095c97b162b9fe0
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
This case report highlights the immune-related adverse events (irAEs) that occurred during the treatment of esophageal cancer with Tislelizumab and discusses management strategies, indicating that photodynamic therapy (PDT) may be an optimal adjuncti
Externí odkaz:
https://doaj.org/article/417d298b768c4b67b81cd29553793ad3
Autor:
Haitian LI, Qing LIU, Bin LI, Yuzhen CHEN, Junping LIN, Yuqi MENG, Haiming FENG, Zhizhong ZHENG, Yiming HUI
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 6, Pp 421-430 (2024)
Background and objective Lung cancer is the cancer with the highest incidence and mortality rates in China, and non-small cell lung cancer (NSCLC) accounts for 80%-85% of all malignant lung tumors. Currently, surgical treatment remains the primary tr
Externí odkaz:
https://doaj.org/article/f24a54f5768d4df39e5475bb00eb50ae
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Programmed Death Receptor 1 (PD-1) inhibitors, when combined with chemotherapy, have exhibited notable effectiveness in enhancing the survival outcomes of patients afflicted with advanced gastric cancer. However, it is important to acknowled
Externí odkaz:
https://doaj.org/article/f05c8893e378418196ce28738cd77bf7